Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection

The objectives were to determine if PCV2 vaccination is effective in reducing disease and lesions associated with PRRSV and PCV2 coinfection and if there is a difference between intradermal (ID) and intramuscular (IM) route of PCV2 vaccination. Seventy-four, 21-day-old pigs were randomly allocated into one of six groups. On day 0, pigs were vaccinated with 2ml Suvaxyn((R)) PCV2 One Dose (Fort Dodge Animal Health, Inc.) by intramuscular (VAC-M-COINF) or intradermal (VAC-D-COINF) routes. On day 28, pigs were either singularly (PRRSV-only, PCV2-only) or coinfected (COINF) with PRRSV and PCV2. All pigs in all groups were necropsied on day 42. All vaccinated pigs seroconverted (IgM, IgG, and neutralizing antibodies) to PCV2 between 14 and 28 days post-vaccination. After challenge, all groups inoculated with PRRSV had reduced average daily gain compared to CONTROLS and PCV2-only (P<0.001). COINF pigs had significantly (P<0.05) reduced anti-PCV2-IgG antibody levels and neutralizing antibody levels compared to both vaccinated groups. COINF pigs had more severe lung lesions compared to VAC-M-COINF (P<0.05). COINF pigs had higher amounts of PCV2 DNA in serum samples and feces (P<0.05) and increased amounts of PCV2 in lymphoid tissues (P<0.05) compared to both vaccinated groups. In summary, PCV2 vaccination was effective at inducing a neutralizing antibody response and significantly reducing PCV2-associated lesions and PCV2 viremia in pigs coinfected with PCV2 and PRRSV. Differences between intradermal and intramuscular routes of vaccine administration were not observed.     

猪圆环病毒病和猪繁殖与呼吸综合征二联灭活疫苗免疫效力

利用猪圆环病毒病(PCVD)和猪繁殖与呼吸综合征(PRRS)二联灭活疫苗免疫4周龄仔猪,免疫后7、14、21、28d采血,测定免疫后血清中抗PRRSV、PCV中和抗体和ELISA抗体较价,并于免疫后28d分别用PRRSV和PCV2攻毒,攻毒后每日检测猪体温和观察临床症状,于攻毒后21d所有存活猪全部扑杀,分别对每头猪肺、肝、脾、淋巴结、心和血进行剖解病理和组织病理学观察及PRRSV和PCV2核酸检测,以确定该疫苗免疫保护率。结果表明,所有试验猪于免疫后7d血清抗体开始检出,28d达到峰值,免疫后28dPRRSV和PCV2攻毒保护率均为100%(5/5)。     

Effect of orally administered Lactobacillus casei on porcine reproductive and respiratory syndrome (PRRS) virus vaccination in pigs

The purpose of this study was to determine whether intranasal/oral administration of probiotics can assist vaccination efficacy against an important swine pathogen, porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV). A controlled challenge trial was performed employing: (a) pigs vaccinated against PRRS and treated with a Lactobacillus casei, (b) pigs vaccinated against PRRS only, (c) pigs treated with L. casei only, and (d) pigs neither vaccinated against PRRS nor treated with L. casei. All pigs were challenged intranasally with a wild PRRSV strain. There was no difference in clinical signs or rectal temperature among the four groups. However, pigs that received L. casei gained significantly more weight than pigs that did not. Vaccinated pigs did not gain more weight than nonvaccinated pigs. Vaccinated groups had significantly fewer viraemic pigs on days post-challenge 4, 11 and 17 than nonvaccinated groups of pigs. There was no effect of probiotic on prevalence or duration of viraemia. Among viraemic pigs, there was no significant difference in mean log base(10) titer of PRRS virus among groups. These results suggest that orally administered L. casei does not affect immune response in such a way as to affect PRRS viraemia or nasal shedding. However, it still appears to provide significant benefit when administered during vaccination as indicated by the higher bodyweight gain following PRRS virus infection.     

猪瘟免疫猪接种PRRSV Nsp2Δ1882-2241弱毒疫苗后免疫应答及T细胞表型变化特征

选择17头28日龄的CSFV和PRRSV抗体均为阴性的仔猪,于试验的第1天和第14天分别对其进行猪瘟耐热保护剂活疫苗（兔源）和高致病性猪繁殖与呼吸综合征Nsp2A1882—2241弱毒疫苗免疫。在免疫后的第28、42天采集外周血液,分析特异性抗体表达量和外周血T淋巴细胞表型的变化,评估猪瘟免疫对猪繁殖与呼吸综合征免疫的影响。结果显示,在CSF免疫后第28、42天,CSFV高抗组中的CD4^＋、CD4^＋／CD8^＋、CD4^＋CD8^＋和CD4-CD8数目均比CSFV低抗组高,CD3^＋和CD8^＋细胞数量比CSFV低抗组低;PRRS高抗组中,CD4CD8-细胞含量高于PRRS低抗组;在CSF免疫后第28天,CSFV抗体产生较高（阳性比率为73．33％）,PRRSV抗体产生较低（阳性比率仅为6．67％）。在CSF免疫后的第42天,CSF高抗组中PRRSV抗体阳性比率较CSF低抗组高8．33％。结果表明,CSFV特异性抗体产生高时能增加PRRSV特异性细胞免疫应答,增加CD4^＋细胞、CD4^＋CD8^＋细胞数量,提高机体免疫水平。CD3＋和CD4CD8-细胞应答作用值得重视。     

Comparative evaluation of PRRS virus infection in vaccinated and naïve pigs

The purpose of this study was to evaluate the time-course of the immune response to a field Porcine Respiratory and Reproductive Syndrome virus (PRRSV) strain in PRRS-naïve, untreated pigs, as well as in four groups of age and breed-matched pigs injected with a live attenuated PRRS vaccine, its adjuvant, an inactivated PRRS vaccine and an irrelevant, inactivated Porcine Circovirus type 2 (PCV2) vaccine, respectively. PRRSV infection was confirmed in all groups by PCR and antibody assays. The antibody response measured by ELISA took place earlier in pigs injected with the live attenuated vaccine, which also developed a much stronger serum-neutralizing antibody response to the vaccine strain. Yet, no clear protection was evidenced in terms of viremia against the field virus strain, which showed 11.1% nucleotide divergence in ORF7 from the vaccine strain. In vitro, the interferon (IFN)-γ response to PRRSV was almost absent on PVD 60 in all groups under study, whereas the prevalence of interleukin (IL)-10 responses to PRRSV was fairly high in PCV2-vaccinated animals, only. Results indicate that distinct patterns of immune response to a field PRRSV strain can be recognized in PRRS-vaccinated and naïve pigs, which probably underlies fundamental differences in the development and differentiation of PRRSV-specific immune effector cells.     

豫南地区规模化猪场猪繁殖与呼吸综合征病毒和猪圆环病毒2型抗体检测与分析

为掌握豫南地区规模化猪场中猪繁殖与呼吸综合征病毒（PRRSV）和猪圆环病毒2型（PCV2）疫苗免疫场猪群抗体水平和非疫苗免疫场猪群病原感染情况,试验利用ELISA方法对该地区猪群进行了PRRSV和PCV2抗体水平检测。结果表明,在疫苗免疫猪群中,PRRSV和PCV2抗体合格率分别为68.8%和58.7%,规模越大的猪场合格率越高,200~500头母猪规模场抗体阳性率最高（分别为76.8%和77.4%）,50头母猪以下场最低（分别为48.3%和44.2%）,种猪的合格率均最高,而育肥猪群合格率均最低。在非疫苗免疫猪群中,PRRSV和PCV2抗体阳性率分别为55.6%和65.3%,PRRSV抗体阳性率最低的是100~200头母猪规模场（46.5%）,最高的是50头母猪以下规模场（68.8%）,断奶仔猪和育肥猪群抗体阳性率均在71%以上;随猪场规模越大,PCV2抗体阳性率越低,200~500头母猪规模场抗体阳性率为41.4%,50~100头规模场和50头以下场的阳性率分别为78.9%和78.6%,种公、母猪的PCV2抗体阳性率最低（分别为37.5%和40.4%）,断奶仔猪和育肥猪抗体阳性率较高（分别为82.2%和79.5%）。本研究反映了豫南地区猪繁殖与呼吸综合征（porcine reproductive and respiratory syndrome,PRRS）和猪圆环病毒病（porcine circovirus disease,PCVD）疫苗免疫猪场的疫苗免疫效果和非疫苗免疫猪场病原感染的实际情况和规律,为该地区PRRS和PCVD防制工作提供了理论依据和指导。     

Long‐term administration of a commercial porcine reproductive and respiratory syndrome virus (PRRSV)‐inactivated vaccine in PRRSV‐endemically infected sows

The purpose of this study was to investigate the safety and efficacy of a commercial European porcine reproductive and respiratory syndrome virus (PRRSV)‐inactivated vaccine after 18‐month use in gilts/sows at a farm with high seroprevalence. In a farrow‐to‐finish farm with 1100 sows, all sows and gilts were systematically vaccinated with the PRRS‐inactivated PROGRESSIS® vaccine for a period of 18 months. Farm's reproductive and litter characteristics were longitudinally recorded for this period and historically compared with those of the year prior to vaccination. Serology, employing immunoperoxidase monolayer assay, had confirmed a high prevalence of PRRS‐specific antibodies in most age groups within the farm prior to vaccination. Seroprevalence during the experiment ranged between 0% and 100% in weaners and growers, but remained at stable high levels (>93%) in finishing pigs and gilts throughout all 2‐year period of serology measurements. No local or systemic vaccine side effects were noted throughout the trial period. Vaccinations had resulted over time in a significant improvement of sow reproductive performance (e.g. reduction of premature farrowings, abortions and increase of farrowing rate) and litter characteristics (e.g. increase of the number of live born and weaned pigs and decrease of stillborn, mummified, weak and splay‐legged piglets). It has also been observed that the higher the degree of immunization of a sow, the better the improvement of her reproductive parameters. Sows after vaccination have shown improved characteristics compared to homoparous sows prior to the application of vaccinations in the farm.     

Sow performance in an endemically porcine reproductive and respiratory syndrome (PRRS)-infected farm after sow vaccination with an attenuated PRRS vaccine

The objective of this field study was to evaluate in an endemically porcine reproductive and respiratory syndrome (PRRS) virus-infected farm the reproductive performance of sows after their vaccination with a PRRS attenuated vaccine. In a farrow-to-finish pig farm with history of endemic PRRS virus infection, a total of 200 gilts and sows were used. They were divided in 2 groups of 100 animals. The first group was used as untreated controls, while the animals of the second group were vaccinated against PRRS virus using the attenuated Porcilis PRRS vaccine (Intervet International, The Netherlands) based on European strain. All health and reproductive parameters were recorded from the time of vaccination up to next weaning. No adverse systemic or local reactions or side effects relative to vaccination were noted. Compared to controls, vaccinated sows showed significantly improved farrowing rate (89% versus 78%) and a tendency for fewer returns to oestrus, particularly those at irregular intervals. Fewer sows farrowed prematurely and showed post-partum dysgalactia syndrome, but more live pigs were born and weaned in each litter after vaccination. It was concluded that vaccination of sows with Porcilis PRRS attenuated vaccine in farms with endemic PRRSV infection has beneficial effects on their health and fertility.     

抗猪繁殖与呼吸综合征高免血清的研制

为研制用于治疗和预防猪繁殖与呼吸综合征的高免血清,选取健康育肥猪作为免疫接种对象,用猪繁殖与呼吸综合征灭活苗和弱毒苗作基础免疫和强化免疫,通过优化免疫程序,制备出抗猪繁殖与呼吸综合征高免血清,并进行了临床治疗试验,结果总有效率为86.67%。表明采用这种方法制备猪繁殖与呼吸综合征高免血清是安全有效、切实可行的。     

Identification and clinical assessment of suspected vaccine-related field strains of porcine reproductive and respiratory syndrome virus

OBJECTIVE: To determine the origin and clinical relevance of selected strains of porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV). ANIMALS: 38 pigs without antibodies for PRRSV. PROCEDURE: A seemingly uncommon restriction endonuclease digestion site in a commercially available vaccine strain of attenuated PRRSV was tested for its stability and prevalence under defined conditions. Selected field strains of PRRSV, with or without the restriction-site marker, were subsequently tested in pigs for virulence and for their ability to replicate competitively in pigs simultaneously given the vaccine. RESULTS: Under experimental conditions, the restriction-site marker was stable during long-term infection of pigs. It was not detected in any of the 25 field strains of PRRSV that were isolated before use of the vaccine or 21 of 25 field strains that were isolated after use of the vaccine but that, on the basis of previous testing, were believed unrelated to the vaccine strain. Conversely, it was detected in 24 of 25 field strains that were isolated after use of the vaccine and that, on the basis of previous testing, were believed to be direct-line descendants of the vaccine strain. Putative vaccine-related strains caused more pronounced pathologic changes than did the vaccine strain alone, and they predominated during replication in pigs also given the vaccine strain. CONCLUSIONS: In some swine herds, the vaccine strain may have persisted and mutated to a less attenuated form. CLINICAL RELEVANCE: The potential for persistence and mutation of specific strains of virus should be an important consideration when designing vaccination programs involving attenuated PRRSV.     

Clinical Effects of Experimental Dual Infections with Porcine Reproductive and Respiratory Syndrome Virus Followed by Swine Influenza Virus in Conventional and Colostrum‐deprived Pigs

Previous studies demonstrated that experimental dual infections of pigs with porcine reproductive and respiratory syndrome virus (PRRSV) followed by H1N1 influenza virus cause more severe disease and growth retardation than the respective single virus infections. Here three experiments were undertaken to better define the clinical impact of combined PRRSV‐H1N1 infections in conventional and caesarean‐derived colostrum‐deprived (CDCD) pigs. Groups of pigs were inoculated by aerosol with PRRSV followed by H1N1 at 3‐, 7‐ or 14‐day intervals. During the post‐H1N1 period, mean body temperatures, respiratory signs and mean weight gains in the PRRSV‐H1N1 inoculated groups were recorded and compared with those in uninoculated controls (experiments 1 and 2) or in singly virus‐inoculated pigs (experiment 3). In a first experiment with conventional pigs, the PRRSV‐3d‐H1N1 and PRRSV‐7d‐H1N1 infections induced mean body temperatures >40.5°C during 8 days (peaks 41.1 and 41.6°C, respectively) and mean growth reductions of 3.4 and 4.8 kg, respectively, during the 2 weeks after H1N1, along with marked depression and respiratory disease. The PRRSV‐14d‐H1N1 infection, on the contrary, was largely subclinical. In a second experiment with conventional pigs, PRRSV‐3d‐H1N1 and PRRSV‐7d‐H1N1 infections were clinically milder, with smaller increases in mean body temperatures (peak 40.5°C in both groups) and growth reductions (1.4 and 1.6 kg, respectively). In both groups, only one pig showed prominent general and respiratory signs. In a final experiment with CDCD pigs, PRRSV‐7d‐H1N1 infection had minimal effects on mean clinical performances and growth and, except for one pig that was severely affected, differences with the single virus inoculations were negligible. Thus, both the time interval between infections and the sanitary status of pigs can affect the clinical outcome of dual PRRSV‐H1N1 infections. However, factors so far unknown seem to cause large variations in the clinical response between individual pigs.     

Experimental Dual Infection of Specific Pathogen‐Free Pigs with Porcine Reproductive and Respiratory Syndrome Virus and Pseudorabies Virus

Twenty 6‐week‐old specific pathogen‐free pigs were divided into four groups. On day 0 of the experiment, PRRSV–PRV (n = 6) and PRRSV (n = 4) groups were intranasally inoculated with porcine reproductive and respiratory syndrome virus (PRRSV) (10^5.6 TCID₅₀). On day 7, the PRRSV–PRV and PRV (n = 6) groups were intranasally inoculated with pseudorabies virus (PRV) (10^3.6 TCID₅₀). Control pigs (n = 4) were kept as uninoculated negative controls. Half of the pigs in each group were euthanized and necropsied on day 14 or 21. Clinical signs such as depression and anorexia were observed in the PRRSV–PRV and PRV groups after inoculation with PRV. Although febrile response was observed after virus inoculations, the duration of that response was prolonged in the PRRSV–PRV group compared with the other groups. The lungs in the PRRSV–PRV group failed to collapse and were mottled or diffusely tan and red, whereas the lungs of the pigs in the other groups were grossly normal. Histopathologically, interstitial pneumonia was present in all PRRSV‐inoculated pigs, but the pneumonic lesions were more severe in the PRRSV–PRV group. Mean PRRSV titres of tonsil and lung in the PRRSV–PRV group were significantly (P < 0.05) higher than that in the PRRSV group on day 21. These results indicate that dual infection with PRRSV and PRV increased clinical signs and pneumonic lesions in pigs infected with both viruses, as compared to pigs infected with PRRSV or PRV only, at least in the present experimental conditions.     

Safety and efficacy of vaccination of pregnant gilts against porcine reproductive and respiratory syndrome.

OBJECTIVE: To determine the safety and efficacy of vaccination of pregnant gilts with an attenuated strain of porcine reproductive and respiratory syndrome virus (PRRSV). ANIMALS: 16 pregnant gilts. PROCEDURE: Pregnant gilts free of antibodies for PRRSV were assigned (4 gilts/group) to the following groups: group I, untreated controls; group II, vaccinated on day 60 of gestation; group III, vaccinated on day 60 of gestation and exposed to virulent PRRSV on day 90 of gestation; and group IV, exposed to virulent PRRSV on day 90 of gestation. Safety and efficacy of vaccination was evaluated by group comparisons of prenatal and postnatal survival of fetuses and pigs, respectively, and by the condition and rate of weight gain of liveborn pigs. RESULTS: Collective (prenatal and postnatal) death losses up to day 15 after farrowing (conclusion of study) were similar for groups I (7/47, 14.9%) and II (7/44, 16.9%) but were greater for group III (18/49, 36.7%) and were greater still for group IV (23/37, 62.2%). Mean body weight 15 days after farrowing was greatest for pigs in litters of group I (4.46 kg) and progressively less for the other groups (3.87, 3.76, and 2.18 kg for groups II, III, and IV, respectively). CONCLUSIONS: Using these conditions, vaccination of gilts during midgestation appeared to be safe. However, it provided only partial protection against subsequent exposure to virulent virus. CLINICAL RELEVANCE: Attenuated-PRRSV vaccines may have to be administered to naive gilts > 30 days before conception to provide maximum protection throughout gestation.     

Efficacy of Tilmicosin Phosphate (Pulmotil® Premix) in Feed for the Treatment of a Clinical Outbreak of Actinobacilluspleuropneumoniae Infection in Growing–Finishing Pigs

A double‐blind randomized clinical trial was carried out to investigate the efficacy of tilmicosin (Pulmotil^® premix) for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing–finishing pigs. The effects of tilmicosin administration in the feed at 400 mg/kg and an injection therapy of clinically diseased pigs with long‐acting oxytetracycline (Terramycine^® LA) at 20 mg/kg bodyweight were compared. Both groups, totalling 147 pigs, were compared during a medication period of 15 days and a post‐medication period of 11 days by means of different clinical and performance parameters. During the medication period, the tilmicosin group showed a significant advantage with respect to the number of new disease cases (P < 0.01), and a non‐significant advantage regarding the number of removed pigs (P=0.16), the number of sick pigs that recovered (P=0.27) and the time to recovery (P=0.42). During the post‐medication period, the pigs of the tilmicosin group showed numerical non‐significant benefits (P > 0.05) with respect to the clinical parameters. During the overall study period (26 days), the average daily gain and the feed conversion ratio were both significantly (P < 0.01) better in pigs from the tilmicosin group compared with pigs from the oxytetracycline group. This study demonstrated that in‐feed medication of tilmicosin at a dosage of 400 mg/kg is efficacious for the treatment of a clinical respiratory disease outbreak of A. pleuropneumoniae infection in growing–finishing pigs. Compared with oxytetracycline injection of clinically diseased pigs, the tilmicosin treatment is particularly beneficial in the prevention of new disease cases while increasing or maintaining the performance of the pigs.     

猪繁殖与呼吸综合征病毒非结构蛋白研究进展

猪繁殖与呼吸综合征(PRRS)是由猪繁殖与呼吸综合征病毒(PRRSV)引起的高度接触性传染病。主要引起母猪繁殖障碍,表现为妊娠后期流产,死胎,木乃伊胎及弱仔;各日龄段的猪特别是仔猪感染PRRSV引起呼吸道疾病,以间质性肺炎为特征,论文主要从近几年研究的PRRSV的非结构蛋白特性、免疫学功能、非结构蛋白基因的变异等方面进行分析,阐述非结构蛋白在病毒的增殖、致病力产生的影响,从而为进一步的研究提供一定的理论基础。     

猪繁殖与呼吸综合征病毒GP5蛋白-重组犬1型腺病毒构建及在猪体内免疫特性

本试验根据猪繁殖与呼吸综合征病毒(PRRSV)基因组GP5蛋白的免疫原性,将PRRSV河北分离株GP5基因的表达盒克隆到犬1型腺病毒的感染性基因组的复制非必需区内,转染MDCK细胞,获得了重组病毒,免疫新生仔猪,分别在免疫后0～12周采集血清,通过ELISA检测证明,猪体同时产生了针对犬1型腺病毒和PRRSVGP5的抗体.说明GP5-重组犬1型腺病毒具有作为蓝耳病疫苗的潜力.     

猪繁殖与呼吸综合征抗病育种研究进展

猪繁殖与呼吸综合征(porcine reproductive and respiratory syndrome, PRRS)是由猪繁殖与呼吸综合征病毒(PRRS virus, PRRSV)引起的一种高度接触性传染病，严重危害我国乃至世界养猪业。然而由于PRRSV抗原的多变性，目前包括疫苗接种、药物治疗等在内的防治措施效果不佳。因此，随着现代分子生物学技术的不断发展，基于基因编辑技术对猪PRRS的抗病育种逐渐发展起来。本文简述了PRRS的临床症状，重点回顾了国内外PRRS抗病育种研究进展，通过分析PRRS的致病机制，重点阐述了PRRSV受体及针对不同受体进行编辑的体内及体外抗病毒效果，以期为未来深入研究PRRSV致病机制、开发PRRS抗病品种提供理论依据。     

猪蓝耳病及其综合防控措施

猪繁殖与呼吸综合征（PRRS）俗称猪蓝耳病,是由PRRS病毒（PRRSV）引起的传染病,分为欧洲型和北美型,是目前养猪业最重要的猪病之一。PRRS每年给美国养猪业造成的损失为6.64亿美元（约40亿人民币）,中国的养猪量数倍于美国,因此该病在中国造成的损失应该远大于美国。该病对母猪群的影响主要是降低分娩率,降低产仔数和窝均断奶仔猪数。我国的PRRS以北美型为主,感染后会引起母猪群的繁殖障碍,仔猪、生长育肥猪群的呼吸道问题。2006年我国暴发了由变异株PRRSV引起的高致病性PRRS,该病在全国范围内流行,重创了中国养猪业^[1]。2013年以后,类NADC-30毒株开始在国内逐渐扩散传播,各种重组毒株也不断出现,PRRS的防控变得更加复杂^[2-3]。PRRSV容易变异、毒株多样、感染时间长、防控难度较大。猪群感染PRRS后会造成免疫抑制,易出现各种混合感染和继发感染,这增加防控的难度。文章回顾了PRRS的临床症状、病理变化、病原特性、传播途径、诊断方法与防控措施。在PRRS的防控上,猪场需要良好的生物安全、科学的疫苗免疫与正确的药物方案。文章还探讨了在发生了PRRS感染的猪场,使用替米考星进行控制的效果。     

Efficacy of a type 2 PRRSV modified live vaccine (PrimePac™ PRRS) against a Thai HP-PRRSV challenge

The Chinese highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) has caused a severe threat to the pig population in Southeast Asian countries. The purpose of this study was to investigate the efficacy of a type 2 PRRSV modified live vaccine (PrimePac? PRRS, lineage 7) against a Thai HP-PRRSV (10PL01, lineage 8). Three-week-old PRRSV-free pigs were randomly assigned into three groups. Vaccinated challenged group (group 1, n?=?16) was immunized with PrimePac? PRRS vaccine at 3 weeks old. The unvaccinated challenged group (group 2, n?=?16) was injected with PBS at 3 weeks old, and unvaccinated unchallenged group (group 3, n?=?10) was served as a negative control. At 9 weeks old, all groups, except the negative control group, were challenged with the Thai HP-PRRSV. All pigs were monitored daily during 10 days post-infection (dpi) and were necropsied at 10 and 17 dpi. The results revealed that vaccinated challenged pigs showed significantly lower (p?<?0.05) mean rectal temperatures, clinical respiratory scores, lung lesion scores, and levels of virus load in serum and lung tissue compared with the unvaccinated challenged pigs. Moreover, vaccinated challenged pigs exhibited PRRSV-specific serum neutralizing antibodies at the end of the experiment. Our findings indicated that the studied type 2 PRRSV vaccine provided partial protection against the Thai HP-PRRSV infection based on the body temperature, levels of viremia, and the severity of lung lesions. These results demonstrated that partial protection of PrimePac? PRRS vaccine might be useful for controlling HP-PRRSV infection in the endemic area.